Asunto(s)
Dermatitis Exfoliativa/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Pénfigo/tratamiento farmacológico , Rituximab/uso terapéutico , Diagnóstico Tardío , Dermatitis Exfoliativa/diagnóstico , Femenino , Humanos , Factores Inmunológicos , Persona de Mediana Edad , Pénfigo/diagnóstico , Resultado del TratamientoAsunto(s)
Autoanticuerpos/sangre , Inhibidores de la Dipeptidil-Peptidasa IV/efectos adversos , Penfigoide Ampolloso/inducido químicamente , Penfigoide Ampolloso/inmunología , Anciano , Anciano de 80 o más Años , Autoantígenos/inmunología , Distonina/inmunología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Colágenos no Fibrilares/inmunología , Penfigoide Ampolloso/patología , Índice de Severidad de la Enfermedad , Colágeno Tipo XVIIRESUMEN
Bullous Diseases Unit at the 2nd Department of Dermatology and Venereology, Aristotle University of Thessaloniki was founded with the aim to provide the optimal diagnostic approach and treatment of patients with autoimmune bullous diseases (AΙBD). We processed all AIBD files of patients diagnosed from 2011 to 2014 in order to record all epidemiological data and therapeutic manipulations during monitoring. 57 patients were diagnosed with intraepidermal and 62 with subepidermal bullous diseases. There were 51 cases (89%) of pemphigus vulgaris (PV) and 6 (11%) of pemphigus foliaceus (PF), whereas 45 (73%) patients were diagnosed with bullous pemphigoid (BP), 9 (14%) with mucous membrane pemphigoid (MMP), 3 (5%) with pemphigoid gestationis (PG), 3 (5%) with linear IgA dermatosis (LAD), 1 (2%) with epidermolysis bullosa aquisita (EBA), and 1 patient with an undefined subepidermal AIBD. The mean age of patients within the pemphigus spectrum was 57 years. In the pemphigoid spectrum, the mean age was 72 years. Comorbidities were reported with increasing frequency, as well as treatment options other than systemic corticosteroids, such as adjuvant immunosuppressive agents, which were used to achieve complete remission. This is a report from a tertiary AIBD Referral Center in northern Greece. Our data from a 4-year period contribute to the completion of the global geographic incidence map of AIBD.
Asunto(s)
Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Enfermedades Cutáneas Vesiculoampollosas/diagnóstico , Enfermedades Cutáneas Vesiculoampollosas/epidemiología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Autoinmunes/terapia , Femenino , Grecia , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Enfermedades Cutáneas Vesiculoampollosas/terapiaRESUMEN
is missing (Short communication).
Asunto(s)
Enfermedades Autoinmunes/psicología , Calidad de Vida , Enfermedades Cutáneas Vesiculoampollosas/psicología , Anticuerpos/sangre , Desmogleína 1/inmunología , Grecia , Humanos , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Regression of congenital nevi is usually associated with loss of pigment or halo formation. In rare cases, regression is characterized by sclerosis and hair loss. We describe a rare case of a sclerotic hypopigmented large congenital melanocytic nevus in which a localized scleroderma-like reaction process of regression seemed to have started in utero and progressed throughout early childhood.